SCHEMBL239877

SCHEMBL239877

Clc1nc2c(cnc3cc(-c4ccncc4)nn32)cc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
KDM4E B2RXH2 2/20 0.49
FYN P06241 5/20 0.47
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ALDH1A1 P00352 2/20 0.41
STAT1 P42224 1/20 0.41
MAPT P10636 4/20 0.41
THRB P10828 1/20 0.41
KDR P35968 1/20 0.41
RXFP1 Q9HBX9 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GSK3B P49841 2/20 0.40
CDC7 O00311 1/20 0.40
ROCK2 O75116 1/20 0.40
MAP4K4 O95819 1/20 0.40
PIM1 P11309 1/20 0.40
PRKACA P17612 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2755217 0.87 KDM4E (0.48) NPC1RAB9ASMN1; SMN2KDM4EL3MBTL1
SCHEMBL236310 0.87 KDM4E (0.48) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL238540 0.86 NPC1 (0.45) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL3253997 0.84 NPC1 (0.62) NPC1RAB9ASMN1; SMN2KDM4EMAPK1
SCHEMBL238625 0.84 NPC1 (0.44) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL238454 0.83 HTT (0.49) NPC1RAB9ASMN1; SMN2FYNL3MBTL1
SCHEMBL235881 0.81 RAB9A (0.48) NPC1RAB9ASMN1; SMN2KDM4EMAPK1
SCHEMBL234372 0.80 FYN (0.40) NPC1RAB9ASMN1; SMN2KDM4EFYN
SCHEMBL236731 0.80 RAB9A (0.39) NPC1RAB9ASMN1; SMN2KDM4EMAPK1
SCHEMBL2755164 0.79 RAB9A (0.40) NPC1RAB9ASMN1; SMN2KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885SMN1; SMN2 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.